RAPT Therapeutics (RAPT) Competitors $1.14 0.00 (0.00%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.12 -0.01 (-1.32%) As of 01/31/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RAPT vs. ADCT, SLN, STRO, NBTX, FATE, KYTX, BMEA, TIL, ADAP, and IPHAShould you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include ADC Therapeutics (ADCT), Silence Therapeutics (SLN), Sutro Biopharma (STRO), Nanobiotix (NBTX), Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Biomea Fusion (BMEA), Instil Bio (TIL), Adaptimmune Therapeutics (ADAP), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. RAPT Therapeutics vs. ADC Therapeutics Silence Therapeutics Sutro Biopharma Nanobiotix Fate Therapeutics Kyverna Therapeutics Biomea Fusion Instil Bio Adaptimmune Therapeutics Innate Pharma ADC Therapeutics (NYSE:ADCT) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Is ADCT or RAPT more profitable? RAPT Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat RAPT Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ADC Therapeutics-300.00% N/A -61.33% RAPT Therapeutics N/A -89.10%-76.13% Do analysts recommend ADCT or RAPT? ADC Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 377.61%. RAPT Therapeutics has a consensus target price of $9.56, indicating a potential upside of 738.21%. Given RAPT Therapeutics' higher probable upside, analysts clearly believe RAPT Therapeutics is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00RAPT Therapeutics 1 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.15 Does the media refer more to ADCT or RAPT? In the previous week, ADC Therapeutics and ADC Therapeutics both had 3 articles in the media. RAPT Therapeutics' average media sentiment score of 0.62 beat ADC Therapeutics' score of -0.04 indicating that RAPT Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ADC Therapeutics Neutral RAPT Therapeutics Positive Which has preferable valuation and earnings, ADCT or RAPT? RAPT Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$69.56M2.33-$240.05M-$2.39-0.70RAPT Therapeutics$1.53M26.05-$116.80M-$2.77-0.41 Does the MarketBeat Community believe in ADCT or RAPT? RAPT Therapeutics received 32 more outperform votes than ADC Therapeutics when rated by MarketBeat users. However, 67.44% of users gave ADC Therapeutics an outperform vote while only 62.94% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformADC TherapeuticsOutperform Votes5867.44% Underperform Votes2832.56% RAPT TherapeuticsOutperform Votes9062.94% Underperform Votes5337.06% Do insiders & institutionals believe in ADCT or RAPT? 41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are held by institutional investors. 4.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryRAPT Therapeutics beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks. Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRAPT TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.90M$6.87B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-0.417.6680.0317.24Price / Sales26.05320.221,259.7283.26Price / CashN/A73.5045.9637.70Price / Book0.275.275.124.70Net Income-$116.80M$136.98M$111.40M$224.47M7 Day Performance-3.39%-0.84%2.30%-0.19%1 Month Performance-27.85%-0.02%3.13%0.57%1 Year Performance-95.46%7.51%24.60%20.35% RAPT Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRAPT Therapeutics4.7623 of 5 stars$1.14flat$9.56+738.2%-95.4%$40.90M$1.53M-0.4180Short Interest ↓Gap UpADCTADC Therapeutics2.0634 of 5 stars$1.68-5.4%$8.00+377.6%-46.5%$161.86M$69.56M-0.70310Short Interest ↑News CoverageSLNSilence Therapeutics2.9344 of 5 stars$5.38-5.4%$57.20+962.6%-76.3%$161.53M$31.55M-3.44100Analyst ForecastAnalyst RevisionNews CoverageSTROSutro Biopharma4.16 of 5 stars$1.96-4.2%$11.13+469.1%-55.8%$161.21M$153.73M-1.21240Short Interest ↑NBTXNanobiotix3.2067 of 5 stars$3.38-2.2%$12.00+255.6%-54.0%$159.06M$39.18M0.00100Short Interest ↓FATEFate Therapeutics4.1868 of 5 stars$1.38+3.4%$6.75+390.9%-78.9%$156.60M$63.53M-0.83550Short Interest ↓Positive NewsGap DownKYTXKyverna Therapeutics1.7557 of 5 stars$3.57-1.0%$25.71+621.3%N/A$153.90M$7.03M0.0096Short Interest ↑BMEABiomea Fusion2.8283 of 5 stars$4.21-4.5%$39.36+835.0%-76.9%$152.57MN/A-1.0550Short Interest ↑TILInstil Bio3.1012 of 5 stars$23.02-1.8%$114.00+395.3%+88.6%$148.85MN/A-1.97410Short Interest ↑ADAPAdaptimmune Therapeutics2.4291 of 5 stars$0.57-3.4%$2.79+387.3%-38.5%$147.13M$60.28M-2.61490Short Interest ↑News CoverageIPHAInnate Pharma2.9813 of 5 stars$1.76-0.8%$11.50+555.3%-31.7%$147.12M$66.71M0.00220Short Interest ↓Gap UpHigh Trading Volume Related Companies and Tools Related Companies ADC Therapeutics Competitors Silence Therapeutics Competitors Sutro Biopharma Competitors Nanobiotix Competitors Fate Therapeutics Competitors Kyverna Therapeutics Competitors Biomea Fusion Competitors Instil Bio Competitors Adaptimmune Therapeutics Competitors Innate Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RAPT) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
